We are a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. On May 21, 2018, the U.S. Food and Drug Administration (“FDA”) approved DOPTELET (avatrombopag), which is an orally administered thrombopoietin receptor agonist ("TPO-RA") for the treatment of thrombocytopenia in adult patients with chronic liver disease (“CLD”) scheduled to undergo a procedure.
Company profile
Ticker
DOVA
Exchange
Website
CEO
David S. Zaccardelli
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Dova Pharmaceuticals, Inc.
SEC CIK
Corporate docs
Latest filings (excl ownership)
15-12B
Securities registration termination
22 Nov 19
EFFECT
Notice of effectiveness
19 Nov 19
25-NSE
Exchange delisting
12 Nov 19
POS AM
Prospectus update (post-effective amendment)
12 Nov 19
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Nov 19
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Nov 19
SC 14D9/A
Tender offer solicitation (amended)
12 Nov 19
8-K
Termination of a Material Definitive Agreement
12 Nov 19
SC TO-T/A
Third party tender offer statement (amended)
12 Nov 19
10-Q
2019 Q3
Quarterly report
12 Nov 19
Latest ownership filings
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|